Ann Thorac Med 2017 Oct-Dec;12(4):294-297
Department of Medical Specialties, Rheumatology Section, King Fahad Medical City, Riyadh, KSA.
Download full-text PDF
Rheumatology (Oxford) 2015 Aug 3;54(8):1420-8. Epub 2015 Mar 3.
Institute of Clinical Medicine, Department of Rheumatology.
Objective: To retrospectively evaluate the efficacy and safety of rituximab (Rtx) treatment in patients with anti-synthetase syndrome (ASS) and severe interstitial lung disease (ILD).
Methods: Patients with severe ILD and >12 months follow-up post-Rtx were identified from the Oslo University Hospital ASS cohort (n = 112). Clinical data, including pulmonary function tests (PFTs), were retrospectively collected from medical reports. Read More
Autoimmun Rev 2011 Mar 21;10(5):248-55. Epub 2010 Sep 21.
Université Paris Descartes, Institut Cochin, Inserm U1016, Paris, France.
Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies. ILD develops in up to 75% of patients with SSc overall. However, SSc-ILD evolves to end-stage respiratory insufficiency in only a few patients. Read More
Rheumatology (Oxford) 2010 Feb 15;49(2):271-80. Epub 2009 May 15.
Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, 26504 Rion, Patras, Greece.
Objective: To assess the efficacy of rituximab (RTX) in SSc.
Methods: Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, whereas six patients (control group) received standard treatment alone. Read More
Clin Rheumatol 2016 Sep 23;35(9):2339-45. Epub 2016 Apr 23.
Autoimmune Systemic Diseases Unit Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
This study aims to evaluate the utility of magnetic resonance imaging (MRI) to assess interstitial lung disease (ILD) extent in patients with systemic sclerosis (SSc). Patients with SSc and varying degrees of ILD with a high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), and a chest MRI containing an ultrafast SE sequence performed less than 1 year apart were included in the study. Wells global disease extent and Goh's staging algorithm were used to measure and categorize ILD both for MRI and HRCT. Read More